Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v16.i4.1236

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2280)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

141

HTML

985

Figures (1-2)

167

Tables (1-4)

161

Sum=1454

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

179

Download

375

Sum=554

Publishing Process of This Article

Item

Count

Browse

Download

139

Sum=191

Apr 15, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1236-1247
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1236

Table 2 Clinical outcomes

Variables	Total (n = 102)
Best overall response
CR	10
PR	53
SD	20
PD	19
Objective response rate	61.76%
Disease control rate	81.37%
Median PFS	10.07 months (95%CI: 8.50-11.65)
6-month tumor PFS	70.82% (95%CI: 60.80-78.72)
12-month tumor PFS	36.11% (95%CI: 26.49-45.79)
Median OS	26.43 months (95%CI: 17.00-35.87)
6-month survival	92.63% (95%CI: 85.14-96.42)
12-month survival	84.15% (95%CI: 74.05-90.56)

CR: Complete response; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; SD: Stable disease.

Citation: Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1236